ITMI20021620A1 - Composto ad ativita' antitumorale - Google Patents

Composto ad ativita' antitumorale

Info

Publication number
ITMI20021620A1
ITMI20021620A1 IT2002MI001620A ITMI20021620A ITMI20021620A1 IT MI20021620 A1 ITMI20021620 A1 IT MI20021620A1 IT 2002MI001620 A IT2002MI001620 A IT 2002MI001620A IT MI20021620 A ITMI20021620 A IT MI20021620A IT MI20021620 A1 ITMI20021620 A1 IT MI20021620A1
Authority
IT
Italy
Prior art keywords
activity compound
tumoral activity
fgf
tumoral
men2
Prior art date
Application number
IT2002MI001620A
Other languages
English (en)
Original Assignee
Novuspharma Spa
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novuspharma Spa, Ist Naz Stud Cura Dei Tumori filed Critical Novuspharma Spa
Priority to IT2002MI001620A priority Critical patent/ITMI20021620A1/it
Priority to PCT/EP2003/007963 priority patent/WO2004009083A1/en
Priority to CNA038173352A priority patent/CN1668298A/zh
Priority to US10/522,081 priority patent/US20060258731A1/en
Priority to JP2004522542A priority patent/JP2005537277A/ja
Priority to CA002493202A priority patent/CA2493202A1/en
Priority to AU2003251437A priority patent/AU2003251437A1/en
Priority to AT03765081T priority patent/ATE337001T1/de
Priority to DE60307856T priority patent/DE60307856T2/de
Priority to MXPA05000781A priority patent/MXPA05000781A/es
Priority to EP03765081A priority patent/EP1534271B1/en
Priority to ES03765081T priority patent/ES2271649T3/es
Publication of ITMI20021620A1 publication Critical patent/ITMI20021620A1/it
Priority to US12/313,033 priority patent/US20090130229A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
IT2002MI001620A 2002-07-23 2002-07-23 Composto ad ativita' antitumorale ITMI20021620A1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IT2002MI001620A ITMI20021620A1 (it) 2002-07-23 2002-07-23 Composto ad ativita' antitumorale
CA002493202A CA2493202A1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof
CNA038173352A CN1668298A (zh) 2002-07-23 2003-07-22 抗肿瘤化合物及其治疗用途
US10/522,081 US20060258731A1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof
JP2004522542A JP2005537277A (ja) 2002-07-23 2003-07-22 抗腫瘍化合物及びその治療的使用
PCT/EP2003/007963 WO2004009083A1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof
AU2003251437A AU2003251437A1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof
AT03765081T ATE337001T1 (de) 2002-07-23 2003-07-22 Antitumorverbindung und ihre therapeutischen verwendungen
DE60307856T DE60307856T2 (de) 2002-07-23 2003-07-22 Antitumorverbindung und ihre therapeutischen verwendungen
MXPA05000781A MXPA05000781A (es) 2002-07-23 2003-07-22 Compuesto antitumor y usos terapeuticos del mismo.
EP03765081A EP1534271B1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof
ES03765081T ES2271649T3 (es) 2002-07-23 2003-07-22 Compuesto antitumoral y usos terapeuticos del mismo.
US12/313,033 US20090130229A1 (en) 2002-07-23 2008-11-13 Antitumor uses of compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI001620A ITMI20021620A1 (it) 2002-07-23 2002-07-23 Composto ad ativita' antitumorale

Publications (1)

Publication Number Publication Date
ITMI20021620A1 true ITMI20021620A1 (it) 2004-01-23

Family

ID=30130912

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI001620A ITMI20021620A1 (it) 2002-07-23 2002-07-23 Composto ad ativita' antitumorale

Country Status (12)

Country Link
US (2) US20060258731A1 (it)
EP (1) EP1534271B1 (it)
JP (1) JP2005537277A (it)
CN (1) CN1668298A (it)
AT (1) ATE337001T1 (it)
AU (1) AU2003251437A1 (it)
CA (1) CA2493202A1 (it)
DE (1) DE60307856T2 (it)
ES (1) ES2271649T3 (it)
IT (1) ITMI20021620A1 (it)
MX (1) MXPA05000781A (it)
WO (1) WO2004009083A1 (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068424A1 (en) * 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Indolinone derivatives as receptor tyrosine kinase ihibitors
US7960548B2 (en) * 2005-04-29 2011-06-14 The Ohio State University Research Foundation Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis
WO2008029123A1 (en) * 2006-09-07 2008-03-13 Astrazeneca Ab Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
JP5503655B2 (ja) 2008-09-22 2014-05-28 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RS64122B1 (sr) 2014-11-16 2023-05-31 Array Biopharma Inc Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata
TN2018000027A1 (en) 2015-07-16 2019-07-08 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
BR112018008357A2 (pt) 2015-10-26 2018-11-27 Array Biopharma Inc mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
CR20180501A (es) 2016-04-04 2019-04-05 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a] pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
KR20180129911A (ko) 2016-04-04 2018-12-05 록쏘 온콜로지, 인코포레이티드 소아암을 치료하는 방법
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
PT3800189T (pt) 2016-05-18 2023-07-27 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US6147106A (en) * 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
AR034118A1 (es) * 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis

Also Published As

Publication number Publication date
US20060258731A1 (en) 2006-11-16
JP2005537277A (ja) 2005-12-08
WO2004009083A1 (en) 2004-01-29
ATE337001T1 (de) 2006-09-15
AU2003251437A8 (en) 2004-02-09
EP1534271A1 (en) 2005-06-01
MXPA05000781A (es) 2005-09-21
EP1534271B1 (en) 2006-08-23
ES2271649T3 (es) 2007-04-16
US20090130229A1 (en) 2009-05-21
CN1668298A (zh) 2005-09-14
AU2003251437A1 (en) 2004-02-09
CA2493202A1 (en) 2004-01-29
WO2004009083A8 (en) 2005-02-03
DE60307856D1 (de) 2006-10-05
DE60307856T2 (de) 2007-04-12

Similar Documents

Publication Publication Date Title
ITMI20021620A1 (it) Composto ad ativita' antitumorale
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
BR0210471A (pt) Ligandos do receptor 5-ht e suas utilizações
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE302775T1 (de) Carbolinderivate
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
AU2003229953A8 (en) Phthalazinone derivatives
MY138352A (en) Benzothiazole derivatives
ATE408601T1 (de) Fredericamycin-derivate
NO20052989D0 (no) Terapeutiske forbindelser.
ATE346067T1 (de) Carbolinderivate
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE60317684D1 (de) SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
MY136938A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
EA200600455A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600609A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы